THE SHORT ANSWER
High-Performance Science Teams™ helps diagnostics companies that sell both research-use-only (RUO) and clinical in vitro diagnostic (IVD) products run development as one team, assay development, R&D, regulatory, quality, clinical affairs, operations, medical affairs, and commercial. It targets the behaviors behind RUO data that can’t support an IVD submission, late regulatory strategy, design freezes that never hold, and commercial teams caught between two rulebooks.
Why do diagnostics companies struggle to move from RUO to clinical products?
Most diagnostics companies start the same way: a strong assay, launched as research use only, sold to translational labs and pharma partners. Revenue and publications build. Then the company decides to go clinical, a 510(k), De Novo, or PMA in the U.S., a CE-IVD under the EU IVDR, or a companion diagnostic tied to a pharma partner’s drug program.
That is where two operating models collide. RUO development rewards speed and iteration. Clinical development runs on design controls, verification and validation plans, a design history file, and quality system discipline. The same scientists, the same leadership team, and often the same commercial organization now have to work under both rulebooks at once.
Why is the regulatory environment raising the stakes for diagnostics teams?
Three shifts put more weight on how well diagnostics teams work across functions:
- FDA’s Quality Management System Regulation (QMSR) took effect on February 2, 2026, aligning 21 CFR Part 820 with ISO 13485:2016. Quality is now expected to operate as a management system across the company, not a department.
- The EU IVDR transition was extended by Regulation (EU) 2024/1860, with legacy-device deadlines running to December 2027 for class D, December 2028 for class C, and December 2029 for class B and sterile class A devices — a long runway that is easy to under-staff.
- The U.S. laboratory-developed test landscape shifted when a federal court vacated FDA’s LDT final rule in March 2025 and FDA rescinded it in September 2025, changing the calculus for companies that support LDT customers alongside their own kitted products.
What does team dysfunction look like inside a diagnostics company?
- RUO data that can’t be reused. Assays developed without design-control habits produce analytical data that has to be regenerated for the IVD submission.
- Regulatory strategy decided late. Intended use, claims, and the regulatory pathway are settled after the assay is locked, so clinical validation is designed around a moving target.
- Design freeze that doesn’t hold. Assay development keeps optimizing sensitivity or specificity after verification planning starts, resetting V&V timelines.
- Two cultures under one roof. The tools-and-RUO side and the regulated clinical side use different vocabularies, cadences, and definitions of done — and blame each other for delays.
- Commercial caught between rulebooks. Sales teams face pressure to position RUO products with clinical labs, creating promotional risk and friction with regulatory and medical affairs.
- Companion diagnostic timelines out of sync. The pharma partner’s clinical milestones move; the CDx team hears late and compresses analytical validation or clinical bridging to catch up.
Why don’t new eQMS software, regulatory consultants, or a reorganization fix it?
Diagnostics companies reach for vertical fixes: an eQMS platform for QMSR, a regulatory consultancy for the submission, a new Head of Quality, a split into separate research and clinical business units. Each can be the right call. None changes how assay development, regulatory, quality, and commercial decide together — and splitting the organization often just moves the seam.
The failure pattern is horizontal: decisions that belong to several functions but are owned by none. It needs a horizontal fix.
How does High-Performance Science Teams™ work for diagnostics teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model to diagnostics leadership teams and core product teams, working on live programs, live submissions, and live partner commitments.
| Program-risk pattern | Root behavior | What HPT installs |
| RUO data not usable for IVD | Regulatory and quality brought in after development | Regulatory, quality, and clinical affairs seated in the core team from feasibility onward |
| Late intended-use and pathway decisions | No clear owner for cross-functional calls | A decision charter naming who decides intended use, claims, and pathway — and by when |
| Design freeze that slips | No agreed rule for “good enough” | A freeze protocol tied to target performance specifications, with a named decision owner |
| RUO vs. clinical culture clash | Different goals and definitions of done | Shared program goals and working norms that span both sides of the business |
| Commercial–regulatory friction | Disagreement handled by escalation | A conflict protocol that settles positioning and claims questions in the room |
| CDx timeline surprises | Partner milestones held by one person | Cross-functional partner team with early-warning norms and shared accountability |
What is outside the scope of the program?
High-Performance Science Teams™ is not regulatory consulting, clinical study design, or reimbursement strategy. It works alongside your regulatory advisors and quality systems, making the team that uses them faster and more aligned.
How does this connect to the commercial team?
Bench to Business™, our companion program, coaches the field application scientists, clinical account managers, and pharma partnership leads who carry diagnostics to customers — including how to communicate data accurately across RUO and clinical audiences. Many diagnostics companies run both programs as they move into regulated markets.
Who is it for?
CEOs, CTOs and CSOs, and VPs of R&D, Assay Development, Regulatory Affairs, Quality, Clinical Affairs, Medical Affairs, and Commercial at molecular, NGS, immunoassay, and digital pathology diagnostics companies — especially those converting RUO products to IVD, preparing for QMSR or IVDR milestones, or developing companion diagnostics with pharma partners.
How do we get started?
Start with the Science Team 360™ — a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your diagnostics team. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
What is the difference between an RUO and an IVD product?
A research-use-only (RUO) product is labeled for research and may not be used for clinical diagnostic purposes. An in vitro diagnostic (IVD) product is intended for clinical use and must meet regulatory requirements such as FDA clearance or approval, or CE marking under the EU IVDR, including design controls and quality system compliance.
Why do RUO-to-IVD transitions take longer than planned?
Common causes are team-level: RUO development done without design-control discipline, intended use and regulatory pathway decided late, design freezes that slip, and gaps between assay development, regulatory, quality, and commercial.
When did FDA’s QMSR take effect?
FDA’s Quality Management System Regulation, which aligns 21 CFR Part 820 with ISO 13485:2016, took effect on February 2, 2026.
Does High-Performance Science Teams™ replace regulatory consultants?
No. It is not regulatory consulting. It improves how your internal team decides, shares information, and holds itself accountable while working with regulatory and quality advisors.
How do we start?
With the Science Team 360™, a confidential diagnostic that shows where alignment, decision rights, and accountability break down across your R&D, regulatory, quality, and commercial teams.
Sources
- U.S. FDA, “Quality Management System Regulation (QMSR)” — https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
- BSI, “IVDR Transition Timelines Extended” (Regulation (EU) 2024/1860), July 2024 — https://www.bsigroup.com/en-US/insights-and-media/media-center/press-releases/2024/july/ivdr-transition-timelines-extended/
- The FDA Law Blog, “Federal District Court Vacates FDA’s Laboratory Developed Tests Final Rule,” April 2025 — https://www.thefdalawblog.com/2025/04/federal-district-court-vacates-fdas-laboratory-developed-tests-final-rule/
- AHA News, “FDA vacates final rule regulating lab-developed tests as medical devices,” September 18, 2025 — https://www.aha.org/news/headline/2025-09-18-fda-vacates-final-rule-regulating-lab-developed-tests-medical-devices
- Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.